Benvenuti nel sito del Gruppo Oncologico del Nord Ovest

Chi Siamo Mission

Scopri i Centri Partecipanti

Guarda Contattaci

Pubblicazioni 2017 – 2014

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer British Journal of Cancer (2017), 1–6 | doi: 10.1038/bjc.2016.413 Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest European Journal of Cancer xx (2016) 1e11…

Pubblicazioni 2013 – 2004

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013 Aug;24(8):2062-7. doi: 10.1093/annonc/mdt165. Epub 2013 May 10. Outcome of second-line treatment after first-line chemotherapy with the GONO…